Results of two trials of balstilimab (anti-PD1) alone and in combination with zalifrelimab (anti-CTLA-4) in patients with advanced cervical cancer (SCC or adenocarcinoma) progressing after platinum therapy, were presented at ESMO 2020 with higher response rates seen in the trial of combination therapy [27]. Here, CTLA4 is linked to cervical carcinoma.